Pancreatic cancer tumour initiating cells: The molecular regulation and therapeutic values

Journal of Cellular and Molecular Medicine

Volumn 16, Issue 5, 2012, Pages 988-994

  Ni, Xiaoling ^a,b   Long, Jiang ^b,c   Cen, Putao ^a   Chen, Leon ^a   Yang, Jingxuan ^a   Li, Min ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b FUDAN UNIVERSITY   (China)

^c FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

Author keywords

MicroRNA; Pancreatic cancer; Tumour initiating cells

Indexed keywords

ANTINEOPLASTIC AGENT; MICRORNA; NOTCH RECEPTOR; SONIC HEDGEHOG PROTEIN;

ADENOCARCINOMA; ANIMAL; CELL TRANSFORMATION; DRUG EFFECT; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION; HUMAN; METABOLISM; MOUSE; PANCREAS TUMOR; REVIEW; SIGNAL TRANSDUCTION;

ADENOCARCINOMA; ANIMALS; ANTICARCINOGENIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; HEDGEHOG PROTEINS; HUMANS; MICE; MICRORNAS; PANCREATIC NEOPLASMS; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION;

ERINACEIDAE;

EID: 84860324543     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2011.01478.x     Document Type: Review

References (76)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010; 60: 277-300.
2. Siegel R, Ward E, Brawley O, et al. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011; 61: 212-36.
3. Burris HA, 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997; 15: 2403-13.
4. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007; 25: 1960-6.
5. Long J, Zhang Y, Yu X, et al. Overcoming drug resistance in pancreatic cancer. Expert Opin Ther Targets. 2011; 15: 817-28.
6. Yu X, Zhang Y, Chen C, et al. Targeted drug delivery in pancreatic cancer. Biochim Biophys Acta. 2010; 1805: 97-104.
7. Takaishi S, Okumura T, Wang TC. Gastric cancer stem cells. J Clin Oncol. 2008; 26: 2876-82.
8. Saikawa Y, Fukuda K, Takahashi T, et al. Gastric carcinogenesis and the cancer stem cell hypothesis. Gastric Cancer. 2010; 13: 11-24.
9. Bruce WR, Van Der Gaag H. A quantitative assay for the number of murine lymphoma cells capable of proliferation in vivo. Nature. 1963; 199: 79-80.
10. Park CH, Bergsagel DE, McCulloch EA. Mouse myeloma tumour stem cells: a primary cell culture assay. J Natl Cancer Inst. 1971; 46: 411-22.
11. Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994; 367: 645-8.
12. Dorado J, Lonardo E, Miranda-Lorenzo I, et al. Pancreatic cancer stem cells: new insights and perspectives. J Gastroenterol. 2011; 46: 966-73.
13. Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumourigenic breast cancer cells. Proc Natl Acad Sci USA. 2003; 100: 3983-8.
14. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature. 2004; 432: 396-401.
15. Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al. Identification and expansion of human colon-cancer-initiating cells. Nature. 2007; 445: 111-5.
16. Ma S, Chan KW, Hu L, et al. Identification and characterization of tumourigenic liver cancer stem/progenitor cells. Gastroenterology. 2007; 132: 2542-56.
17. Frank NY, Schatton T, Frank MH. The therapeutic promise of the cancer stem cell concept. J Clin Invest. 2010; 120: 41-50.
18. Li C, Heidt DG, Dalerba P, et al. Identification of pancreatic cancer stem cells. Cancer Res. 2007; 67: 1030-7.
19. Hermann PC, Huber SL, Herrler T, et al. Distinct populations of cancer stem cells determine tumour growth and metastatic activity in human pancreatic cancer. Cell Stem Cell. 2007; 1: 313-23.
20. Shah AN, Summy JM, Zhang J, et al. Development and characterization of gemcitabine-resistant pancreatic tumour cells. Ann Surg Oncol. 2007; 14: 3629-37.
21. Rasheed ZA, Yang J, Wang Q, et al. Prognostic significance of tumourigenic cells with mesenchymal features in pancreatic adenocarcinoma. J Natl Cancer Inst. 2010; 102: 340-51.
22. Kim MP, Fleming JB, Wang H, et al. ALDH activity selectively defines an enhanced tumour-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma. PLoS One. 2011; doi: 10.1371/journal.pone.0020636.
23. Dvorak HF. Tumours: wounds that do not heal. Similarities between tumour stroma generation and wound healing. N Engl J Med. 1986; 315: 1650-9.
24. Mani SA, Guo W, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133: 704-15.
25. Shankar S, Nall D, Tang SN, et al. Resveratrol inhibits pancreatic cancer stem cell characteristics in human and KrasG12D transgenic mice by inhibiting pluripotency maintaining factors and epithelial-mesenchymal transition. PLoS One. 2011; doi: 10.1371/journal.pone.0016530.
26. Berman DM, Karhadkar SS, Maitra A, et al. Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature. 2003; 425: 846-51.
27. Jimeno A, Feldmann G, Suarez-Gauthier A, et al. A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development. Mol Cancer Ther. 2009; 8: 310-4.
28. Ohishi K, Katayama N, Shiku H, et al. Notch signalling in hematopoiesis. Semin Cell Dev Biol. 2003; 14: 143-50.
29. Sriuranpong V, Borges MW, Ravi RK, et al. Notch signaling induces cell cycle arrest in small cell lung cancer cells. Cancer Res. 2001; 61: 3200-5.
30. Shou J, Ross S, Koeppen H, et al. Dynamics of notch expression during murine prostate development and tumourigenesis. Cancer Res. 2001; 61: 7291-7.
31. Miyamoto Y, Maitra A, Ghosh B, et al. Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumourigenesis. Cancer Cell. 2003; 3: 565-76.
32. Mumm JS, Kopan R. Notch signaling: from the outside in. Dev Biol. 2000; 228: 151-65.
33. Wang Z, Zhang Y, Li Y, et al. Down-regulation of Notch-1 contributes to cell growth inhibition and apoptosis in pancreatic cancer cells. Mol Cancer Ther. 2006; 5: 483-93.
34. Bao B, Wang Z, Ali S, et al. Notch-1 induces epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells. Cancer Lett. 2011; 307: 26-36.
35. Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov. 2010; 9: 775-89.
36. Hatfield SD, Shcherbata HR, Fischer KA, et al. Stem cell division is regulated by the microRNA pathway. Nature. 2005; 435: 974-8.
37. He L, Thomson JM, Hemann MT, et al. A microRNA polycistron as a potential human oncogene. Nature. 2005; 435: 828-33.
38. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature. 2005; 435: 834-8.
39. Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumours defines cancer gene targets. Proc Natl Acad Sci USA. 2006; 103: 2257-61.
40. Iorio MV, Ferracin M, Liu CG, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005; 65: 7065-70.
41. Iorio MV, Visone R, Di Leva G, et al. MicroRNA signatures in human ovarian cancer. Cancer Res. 2007; 67: 8699-707.
42. Boren T, Xiong Y, Hakam A, et al. MicroRNAs and their target messenger RNAs associated with endometrial carcinogenesis. Gynecol Oncol. 2008; 110: 206-15.
43. Murakami Y, Yasuda T, Saigo K, et al. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumourous tissues. Oncogene. 2006; 25: 2537-45.
44. Michael MZ, van Holst Pellekaan NG, et al. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res. 2003; 1: 882-91.
45. Nguyen GH, Schetter AJ, Chou DB, et al. Inflammatory and microRNA gene expression as prognostic classifier of Barrett's-associated esophageal adenocarcinoma. Clin Cancer Res. 2010; 16: 5824-34.
46. Dacic S, Kelly L, Shuai Y, et al. miRNA expression profiling of lung adenocarcinomas: correlation with mutational status. Mod Pathol. 2010; 23: 1577-82.
47. Bloomston M, Frankel WL, Petrocca F, et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA. 2007; 297: 1901-8.
48. Ji Q, Hao X, Zhang M, et al. MicroRNA miR-34 inhibits human pancreatic cancer tumour-initiating cells. PLoS One. 2009; 4: e6816. doi: 10.1371/journal.pone.0006816.
49. Liu C, Kelnar K, Liu B, et al. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med. 2011; 17: 211-5.
50. Brabletz S, Brabletz T. The ZEB/miR-200 feedback loop-a motor of cellular plasticity in development and cancer?EMBO Rep. 2010; 11: 670-7.
51. Christoffersen NR, Silahtaroglu A, Orom UA, et al. miR-200b mediates post-transcriptional repression of ZFHX1B. RNA. 2007; 13: 1172-8.
52. Burk U, Schubert J, Wellner U, et al. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep. 2008; 9: 582-9.
53. Gregory PA, Bert AG, Paterson EL, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol. 2008; 10: 593-601.
54. Hurteau GJ, Carlson JA, Spivack SD, et al. Overexpression of the microRNA hsa-miR-200c leads to reduced expression of transcription factor 8 and increased expression of E-cadherin. Cancer Res. 2007; 67: 7972-6.
55. Korpal M, Lee ES, Hu G, et al. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem. 2008; 283: 14910-4.
56. Park SM, Gaur AB, Lengyel E, et al. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev. 2008; 22: 894-907.
57. Wellner U, Schubert J, Burk UC, et al. The EMT-activator ZEB1 promotes tumourigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol. 2009; 11: 1487-95.
58. Li Y, VandenBoom TG, 2nd, Kong D, et al. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res. 2009; 69: 6704-12.
59. Krichevsky AM, Gabriely G. miR-21: a small multi-faceted RNA. J Cell Mol Med. 2009; 13: 39-53.
60. Cai X, Hagedorn CH, Cullen BR. Human microRNAs are processed from capped, polyadenylated transcripts that can also function as mRNAs. RNA. 2004; 10: 1957-66.
61. Fujita S, Ito T, Mizutani T, et al. miR-21 Gene expression triggered by AP-1 is sustained through a double-negative feedback mechanism. J Mol Biol. 2008; 378: 492-504.
62. Meng F, Henson R, Wehbe-Janek H, et al. MicroRNA-21 regulates expression of the PTEN tumour suppressor gene in human hepatocellular cancer. Gastroenterology. 2007; 133: 647-58.
63. Meng F, Henson R, Lang M, et al. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology. 2006; 130: 2113-29.
64. Bao B, Ali S, Kong D, et al. Anti-tumour activity of a novel compound-CDF is mediated by regulating miR-21, miR-200, and PTEN in pancreatic cancer. PLoS One. 2011; doi: 10.1371/journal.pone.0017850.
65. Mueller MT, Hermann PC, Witthauer J, et al. Combined targeted treatment to eliminate tumourigenic cancer stem cells in human pancreatic cancer. Gastroenterology. 2009; 137: 1102-13.
66. Wang Z, Zhang Y, Banerjee S, et al. Notch-1 down-regulation by curcumin is associated with the inhibition of cell growth and the induction of apoptosis in pancreatic cancer cells. Cancer. 2006; 106: 2503-13.
67. Kallifatidis G, Labsch S, Rausch V, et al. Sulforaphane increases drug-mediated cytotoxicity toward cancer stem-like cells of pancreas and prostate. Mol Ther. 2011; 19: 188-95.
68. Srivastava RK, Tang SN, Zhu W, et al. Sulforaphane synergizes with quercetin to inhibit self-renewal capacity of pancreatic cancer stem cells. Front Biosci (Elite Ed). 2011; 3: 515-28.
69. Zimmerman AL, Wu S. MicroRNAs, cancer and cancer stem cells. Cancer Lett. 2011; 300: 10-9.
70. Sureban SM, May R, Lightfoot SA, et al. DCAMKL-1 regulates epithelial-mesenchymal transition in human pancreatic cells through a miR-200a-dependent mechanism. Cancer Res. 2011; 71: 2328-38.
71. Pramanik D, Campbell NR, Karikari C, et al. Restitution of tumour suppressor microRNAs using a systemic nanovector inhibits pancreatic cancer growth in mice. Mol Cancer Ther. 2011; 10: 1470-80.
72. Fojo T. Multiple paths to a drug resistance phenotype: mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and microRNAs. Drug Resist Updat. 2007; 10: 59-67.
73. Giovannetti E, Erozenci A, Smit J, et al. Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice. Crit Rev Oncol Hematol. 2011; doi: 10.1016/j.critrevonc.2011.03.010.
74. David M, Lepage C, Jouve JL, et al. Management and prognosis of pancreatic cancer over a 30-year period. Br J Cancer. 2009; 101: 215-8.
75. Fusi A, Reichelt U, Busse A, et al. Expression of the stem cell markers nestin and CD133 on circulating melanoma cells. J Invest Dermatol. 2011; 131: 487-94.
76. Iinuma H, Watanabe T, Mimori K, et al. Clinical significance of circulating tumour cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer. J Clin Oncol. 2011; 29: 1547-55.